Comparative Pharmacology
Head-to-head clinical analysis: ARISTOGEL versus RAYOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOGEL versus RAYOS.
ARISTOGEL vs RAYOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, activating gene transcription and increasing protein synthesis.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
Aristogel is a topical gel containing 1% testosterone. The recommended adult dose is 5 g (50 mg testosterone) applied once daily to clean, dry, intact skin of shoulders, upper arms, and/or abdomen. Apply at approximately the same time each day, preferably in the morning.
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
None Documented
None Documented
Terminal elimination half-life is 12 hours. Given dosing frequency, steady-state achieved within 2 days; accumulation minimal with standard dosing.
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
Primarily renal (80%) as unchanged drug; 20% fecal via biliary elimination.
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Category C
Category C
Corticosteroid
Corticosteroid